Protein kinases are closely related to the pathogenesis of many diseases such as tumors, inflammations, and autoimmunity. Because of its mutation, overexpression and imbalance, protein kinases play vital roles in the pathogenesis of cancer and have become the most important drug targets in the past 20 years. The kinase inhibitor drugs currently on the market are mainly concentrated on more than 40 kinase targets, mainly on receptor tyrosine kinases, non-receptor tyrosine kinases, and serine kinases. Among them, EGFR, ABL, ALK, JAK and VEGFR are the most targeted proteins. Based on this, the KICD database lists 242 entries from published articles, covering all small molecular structures with kinase inhibitory effects that have been marketed and are under clinical research. Each item of KICD provides detailed information on small molecule kinase inhibitors, such as the structure of each small molecule (SMILE), IUPAC nomenclature, targets, adaptation diseases, and related literature patents, etc. Meanwhile, the classification of each kinase small molecule Inhibitor’s corresponding targets is also included. By establishing published kinase inhibitor database and combining with artificial intelligence algorithms, new small-molecule kinase inhibitors with better activity can be obtained, which helps to improve the discovery efficiency of new small-molecule inhibitors.
